<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Chemokines play an important role in the pathogenesis of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> induces several fibrogenic chemokines, namely monocyte chemoattractant protein-1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1) and transforming growth factor-beta </plain></SENT>
<SENT sid="2" pm="."><plain>The progression of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> can be retarded by <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> (ACEIs) in patients with type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We examined if blockade of the renin-angiotensin system lowered urinary levels of the chemokine <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 and correlated urinary <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 (uMCP-1) with parameters of renal function and <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism before and after 1 year of treatment with an <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: In 22 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in stages 3-5, treatment with the ACEI <z:chebi fb="0" ids="43755">lisinopril</z:chebi> was initiated </plain></SENT>
<SENT sid="5" pm="."><plain>Before treatment and after 12 months of continuous therapy, <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance, uMCP-1 levels, BMI, HbA(1c), and serum cholesterol were assessed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="43755">Lisinopril</z:chebi> treatment improved renal function </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000093'>Proteinuria</z:hpo> decreased from 410 +/- 662 mg per 24 h to 270 +/- 389 mg per 24 h </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="16737">Creatinine</z:chebi> clearance rose from 61 +/- 26 to 77 +/- 41 ml/min </plain></SENT>
<SENT sid="9" pm="."><plain>Urinary <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 levels decreased from 0.456 +/- 0.22 ng/mg <z:chebi fb="0" ids="16737">creatinine</z:chebi> to 0.08 +/- 0.096 ng/mg <z:chebi fb="0" ids="16737">creatinine</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>The change in uMCP-1 correlated significantly (r = 0.61, P &lt; 0.001) with the change in <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>No other parameter correlated with the improvement in renal function </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Blockade of the renin-angiotensin system in type 2 diabetic patients with diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> reduces uMCP-1 levels and improves renal function </plain></SENT>
<SENT sid="13" pm="."><plain>Because <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 induces monocyte immigration and differentiation to macrophages, which augment extracellular matrix production and <z:hpo ids='HP_0005576'>tubulointerstitial fibrosis</z:hpo>, pharmacological reduction of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> may also exert its beneficial effects in diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> by downregulation of renal <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 </plain></SENT>
</text></document>